Table 2.
Patient baseline characteristics
| Variable, n (%) | All Patients |
Genotyped |
||||
|---|---|---|---|---|---|---|
| Genotyped n=286 | Non-genotyped n=324 | P Valuea (Genotyped vs. Non-genotyped) | Sunitinib n=142 | Placebo n=144 | P Value (Sunitinib vs. Placebo) | |
| Age, years | ||||||
| <65 | 195 (68.2) | 258 (79.6) | 0.002 | 95 (66.9) | 100 (69.4) | 0.704 |
| ≥65 | 91 (31.8) | 66 (20.4) | 47 (33.1) | 44 (30.6) | ||
| Sex | ||||||
| Male | 206 (72.0) | 241 (74.4) | 0.522 | 97 (68.3) | 109 (75.7) | 0.188 |
| Female | 80 (28.0) | 83 (25.6) | 45 (31.7) | 35 (24.3) | ||
| Race | ||||||
| White | 258 (90.2) | 254 (78.4) | <0.001 | 127 (89.4) | 131 (91.0) | 0.097 |
| Asian | 17 (5.9) | 59 (18.2) | 11 (7.7) | 6 (4.2) | ||
| Other | 11 (3.8) | 11 (3.4) | 4 (2.8) | 7 (4.9) | ||
| ECOG PS | ||||||
| 0 | 208 (72.7) | 237 (73.1) | 0.730 | 101 (71.1) | 107 (74.3) | 0.818 |
| 1 | 75 (26.2) | 86 (26.5) | 39 (27.5) | 36 (25.0) | ||
| 2 | 1 (0.3) | 0 | 1 (0.7) | 1 (0.7) | ||
| UISS group | ||||||
| T3 lowb | 86 (30.1) | 139 (42.9) | 0.009 | 41 (28.9) | 45 (31.3) | 0.805 |
| T3 highc | 172 (60.1) | 158 (48.8) | 89 (62.7) | 83 (57.6) | ||
| T4, N0 or NX, M0d | 5 (1.7) | 3 (0.9) | 2 (1.4) | 3 (2.1) | ||
| Any T, N+, M0d | 23 (8.0) | 24 (7.4) | 10 (7.0) | 13 (9.0) | ||
P values calculated using Fisher’s exact test.
a
Genotyped vs. non-genotyped; unadjusted for multiplicity.
b
N0 or NX, M0, any Fuhrman grade and ECOG PS 0 or N0 or NX, M0, Fuhrman grade 1 and ECOG PS ≥1.
c
N0 or NX, M0, Fuhrman grade ≥2 and ECOG PS ≥1.
d
Any Fuhrman grade and any ECOG PS.
Abbreviations: ECOG PS, Eastern Cooperative Oncology Group performance status.